OncoMatch/Clinical Trials/NCT07053488

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

Is NCT07053488 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver diseases.

Treatment: Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver — This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation. Donor livers will have HLA-A and HLA-B genes knocked out, and HLA class II expression disabled (by targeting the CIITA transactivator gene), aiming to create a "hypoimmunogenic" organ less prone to rejection. The edited liver is then transplanted into patients with end-stage liver disease. The primary focus is on safety and feasibility - determining whether a CRISPR-edited liver can be transplanted successfully and function normally - as well as evaluating reductions in immune response (acute rejection, anti-donor T cell activation) and graft function over time.